All News

Patients with hepatitis C virus treated with direct acting antiviral drugs showed successful long-term outcomes regardless of receiving opioid substitution therapy for drug addiction.

Patients receiving anticoagulation that need to have an invasive procedure performed may require a temporary interruption in their anticoagulation therapy to limit bleed risk.

Using a drug that increases GABA synthesis and possibly escalates intraneuronal dopamine in a population that is more likely to have behavior health concerns may prove to be an unsafe option.

An FDA-approved mobile application for adults with opioid use disorder (OUD) is now available by prescription. Pear Therapeutics’ reSET-O app aims to increase retention for adults who are in outpatient treatment programs.

The world is rapidly moving towards the adoption and seamless integration of artificial intelligence (AI), including machine learning as a subset of AI, throughout our daily lives.

A newly study published study aimed to distinguish between uninfected cells and latently infected cells, with hopes that eradicating the latent reservoirs could lead to a cure for the disease.

A survey of California 2017 enrollees estimates how drops in enrollment may affect premium increases.

Officials with the FDA have granted Breakthrough Therapy designation to Novartis’ crizanlizumab (SEG101) for the prevention of vaso-occlusive crises (VOCs) in patients of all genotypes with sickle cell disease.

Top news of the day across the health care landscape.

Top news of the day across the health care landscape.

Combination of glecaprevir and pibrentasvir for hepatitis C virus genotype 3 effective over an 8-week treatment duration.

Sun Pharmaceutical Industries, Inc. (SPI) is voluntarily recalling 3 lots of 10 mg vecuronium bromide for injection and 1 lot of 20 mg vecuronium bromide for injection to the hospital level.

Officials with the FDA have granted Breakthrough Therapy designation to Novartis’ crizanlizumab (SEG101) for the prevention of vaso-occlusive crises (VOCs) in patients of all genotypes with sickle cell disease.

Systems now available at a reduced list price of $5,850.

Involvement with the organizations and nonprofit foundations that focus on specialty disease states can help specialty pharmacists gain perspective on the patients they treat.

Crizanlizumab (SEG101, Novartis) is being developed to prevent painful complications called vaso-occlusive crises in patients with sickle cell disease.

Study suggests a new therapy could stop tumor growth by affecting myeloid cell behavior.

Top news of the day across the health care landscape.

Top news of the day across the health care landscape.

Community-acquired pneumonia is a major cause of mortality and morbidity among patients with HIV.

Health care costs in the US represent nearly 20% of the GDP.

The FDA has approved marketing of Lupin Pharmaceuticals’ Lurasidone Hydrochloride Tablets, a generic version of Sunovion Pharmaceuticals, Inc's lurasidone HCl (Latuda) tablets.

Is your life how you imagined it would be, or is it, in reality, more complicated and stressful than you planned? Do you wonder how you managed to achieve all you did including all the patient contacts, and fielding the calls from doctors, too?

A multimethod approach including use of refill data may be the most effective method to identify nonadherence in young patients with chronic kidney disease.

Advancements in cancer therapy have improved survival time for patients with non-small cell lung cancer (NSCLC), according to a new study published in the Journal of Thoracic Oncology.

Controlling the viral reaction of cells latently infected with HIV may have implications for future drug treatments.

Top news of the day across the health care landscape.

Top news of the day across the health care landscape.

A substantial portion of mortality from liver cirrhosis and hepatocellular carcinoma can be attributed to the extrahepatic manifestations associated with hepatitis C virus.

Lupin Pharmaceuticals, Inc. has voluntarily recalled 42 of lots of Ceftriaxone for Injection, USP products at the hospital/physician level. These products were found to contain visual grey particulate matter in reconstituted vials.